Murat Günaltılı

Progression Patterns as Determinants of Post-Progression Survival in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

Objective: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved outcomes in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer; however, most patients eventually develop disease progression. The clinical significance of progression patterns in th...

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.